Comparing two treatment regimens for elderly patients with mantle cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2, multicenter, open-label trial aims to evaluate the efficacy and safety of rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) compared to standard RB therapy in elderly patients with mantle cell lymphoma who are not candidates for high-dose therapy followed by autologous stem cell transplantation. Eligible patients will be randomly assigned to one of the two treatment arms in a 1:1 ratio, with stratification based on age, histologic morphology, and MIPI-C risk score. The study seeks to determine if the alternating regimen provides better outcomes than the standard treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. newly diagnosed, previously untreated, histologically confirmed CD20+ mantle cell lymphoma, confirmed by WHO classification criteria
2. age ≥70 years or 60-69 years if the patients are ineligible for high-dose therapy with autologous stem cell transplantation.
3. ECOG performance status 2 or less
4. Adequate organ functions

   * adequate heart function: LVEF ≥50% by echocardiography or MUGA
   * adequate renal function: serum creatinine ≤ 2.0mg/dL or CrCl ≥40 mL/min based on the Cockcroft-Gault method
   * adequate hepatic function: ≤2.5 times the upper limit of ALT (≤5 times the upper limit of ALT if the elevation is attributed by underlying lymphoma) and ≤2 times the upper limit of ALT (≤3 times the upper limit of total bilirubin if the elevation is attributed by underlying lymphoma)
   * adequate hematologic function: absolute neutrophil counts (ANC) ≥ 1,500/mL, platelet counts ≥ 100,000/mL (any ANC and platelet counts are allowed, if they were related to bone marrow involvement)
5. Written informed consent

Exclusion Criteria:

1. In-situ mantle cell lymphoma
2. Ann Arbor stage 1 disease
3. Prior treatment for Hodgkin lymphoma or non-Hodgkin lymphoma within the last 5 years.
4. Active malignancy within the past 3 years except for localized non-melanoma skin cancer, papillary thyroid cancer, cervical carcinoma in situ, breast cancer in situ, or localized prostate cancer that has been definitely treated,
5. Central nervous system involvement
6. HBsAg (+) or anti-HBc Ab (+) (patients will be eligible if they receive appropriate prophylactic antiviral therapy using entecavir, tenofovir, and so on)
7. History of prior hepatitis C infection (patients positive for HCV IgG will be eligible if they are negative for HCV-RNA)
8. Known history of human immunodeficiency virus (HIV) infection
9. any serious illness or medical conditions that are unstable or could jeopardize the safety of the patient and his/her compliance in the study

   * Congestive heart failure ≥ NYHA class 3
   * Acute coronary syndrome within 6 months (unstable angina or new-onset angina, myocardial infarct, or ventricular arrhythmia)
   * History of significant neurological or psychological disorder including dementia and seizure disorder
   * Severe chronic obstructive pulmonary disease with hypoxemia
   * Cerebrovascular disease including transient ischemic attack within the past 6 months
   * Non-healing wound, ulcer, or bone fracture
   * Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
10. concomitant administration of any other experimental drugs under investigation
11. Known hypersensitivity to bendamustine, rituximab, cytarabine, or mannitol
12. major surgical procedure or significant trauma within 28 days before start of study treatment, open biopsy within 7 days before start of study treatment
13. If the patient's partner is a woman who could possibly get pregnant, men who didn't have a vasectomy must agree to use medically recommended methods for adequate contraception (tubal ligation, intrauterine devices, or barriers \[diaphragm, cervical cap\] in the patient's partner and the use of condoms in men) when sexually active.

Where it's running

• Samsung Medical Center
  Seoul, Gangnam-Gu, South Korea Recruiting

Study contacts

• Study coordinator: kim seok jin, phD
• Email: hjds.shin@samsung.com
• Phone: 82-10-9933-1766

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Bendamustine–Rituximab–Cytarabine plus Zanubrutinib induction followed by zanubrutinib/rituximab with or without sonrotoclax maintenance for newly diagnosed mantle cell lymphoma

  This trial tests whether giving zanubrutinib with a bendamustine‑rituximab‑cytarabine induction and then continuing zanubrutinib with rituximab, with or without sonrotoclax, helps people with newly diagnosed mantle cell lymphoma stay in remission longer.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Phoenix, Arizona and 6 other locations · NCT06854003

• Combination treatment for chronic lymphocytic leukemia and lymphoma

  This study is testing a new combination treatment with sonrotoclax and either zanubrutinib or rituximab to see if it can help patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06839053

• Combining nemtabrutinib and rituximab to treat mantle cell lymphoma

  This study is testing if combining two treatments, nemtabrutinib and rituximab, can help people with newly diagnosed mantle cell lymphoma feel better and live longer.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06572618

• CAR-T-cell treatment for high-risk mantle cell lymphoma

  This study is testing a new CAR-T-cell treatment for high-risk mantle cell lymphoma to see if it works better than standard therapies for younger and healthier elderly patients.

  Recruiting at 2 sites Phase 2 Ludwig-Maximilians - University of Munich · Mainz and 1 other locations · NCT06482684

• Comparing Orelabrutinib with standard treatment for mantle cell lymphoma

  This study is testing if adding a new drug called Orelabrutinib to the standard treatment can help older patients with untreated mantle cell lymphoma feel better and improve their outcomes.

  Recruiting at 19 sites Phase 3 InnoCare Pharma Inc. · Beijing and 38 other locations · NCT06363994

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.